$480,000.00 in Sales Expected for Adverum Biotechnologies Inc (NASDAQ:ADVM) This Quarter

Equities research analysts forecast that Adverum Biotechnologies Inc (NASDAQ:ADVM) will report sales of $480,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Adverum Biotechnologies’ earnings, with estimates ranging from $460,000.00 to $500,000.00. Adverum Biotechnologies posted sales of $830,000.00 during the same quarter last year, which suggests a negative year over year growth rate of 42.2%. The company is scheduled to report its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that Adverum Biotechnologies will report full-year sales of $960,000.00 for the current year, with estimates ranging from $920,000.00 to $1.00 million. For the next fiscal year, analysts anticipate that the company will post sales of $1.42 million, with estimates ranging from $1.00 million to $1.84 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Adverum Biotechnologies.

Adverum Biotechnologies (NASDAQ:ADVM) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.08. Adverum Biotechnologies had a negative return on equity of 31.21% and a negative net margin of 4,505.40%.



A number of equities analysts have recently issued reports on the company. Cowen restated a “buy” rating on shares of Adverum Biotechnologies in a research note on Tuesday, July 9th. Raymond James started coverage on shares of Adverum Biotechnologies in a research note on Thursday, June 13th. They set a “market perform” rating on the stock. Zacks Investment Research downgraded shares of Adverum Biotechnologies from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 30th. SunTrust Banks reduced their price objective on shares of Adverum Biotechnologies from $12.00 to $8.00 and set a “hold” rating on the stock in a report on Friday. Finally, Chardan Capital cut their price target on shares of Adverum Biotechnologies from $10.00 to $6.00 and set a “neutral” rating on the stock in a research note on Friday. Seven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $9.60.

A number of institutional investors and hedge funds have recently modified their holdings of ADVM. Bank of America Corp DE boosted its stake in shares of Adverum Biotechnologies by 185.8% in the 4th quarter. Bank of America Corp DE now owns 40,501 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 26,330 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in Adverum Biotechnologies by 94.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 16,504 shares of the biotechnology company’s stock worth $86,000 after acquiring an additional 8,038 shares during the last quarter. SG Americas Securities LLC acquired a new position in Adverum Biotechnologies during the 1st quarter worth approximately $60,000. JPMorgan Chase & Co. boosted its position in Adverum Biotechnologies by 12.7% during the 1st quarter. JPMorgan Chase & Co. now owns 3,297,793 shares of the biotechnology company’s stock worth $17,281,000 after acquiring an additional 371,461 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new position in Adverum Biotechnologies during the 1st quarter worth approximately $150,000. 71.78% of the stock is currently owned by hedge funds and other institutional investors.

Adverum Biotechnologies stock traded up $0.04 during mid-day trading on Wednesday, reaching $5.82. The stock had a trading volume of 37,990 shares, compared to its average volume of 2,392,147. The company has a debt-to-equity ratio of 0.12, a quick ratio of 17.79 and a current ratio of 17.79. Adverum Biotechnologies has a fifty-two week low of $2.62 and a fifty-two week high of $16.38. The stock’s 50-day simple moving average is $11.75 and its 200-day simple moving average is $9.24. The firm has a market capitalization of $384.18 million, a PE ratio of -4.94 and a beta of 2.49.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema.

Further Reading: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on Adverum Biotechnologies (ADVM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adverum Biotechnologies (NASDAQ:ADVM)

Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.